Novartis Ag ADR (NVS)
$98.35
0.00 (0.00%)
NVS Stock Quote Delayed 30 Minutes
4 Top Stock Trades for Tuesday: ROKU, ADSK, SPLK, NVS
Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
5,934
Day's Range
-
52-Week Range
$92.19 - $108.78
Dividend & Yield
$3.47 (3.53%)
NVS Stock Predictions, Articles, and Novartis Ag ADR News
Here’s the Real Problem with Altria Overpaying for CRON Stock
Altria Group Inc (NYSE:MO) was the latest in a frenzied string of M&A and partnerships in the cannabis sector. Marijuana stocks have been the target of billion-dollar investments, and the $102 billion market cap company and owner of veteran cigarette brands Marlboro, Parliament, and Virginia Slims, last month that it was investing approximately $1.8 billion in Canadian-based Cronos Group Inc (NASDAQ:CRON), which is listed both on the TSX as well as the NASDAQ.
3 Big Stock Charts for Wednesday: Incyte, FMC and LyondellBasell
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
Novartis News: NVS Stock Sinks Following Alcon Spin-Off
Novartis news about the company's spin-off of Alcon into its own publicly-traded company has NVS stock falling hard on Tuesday.
The Roche Merger Will Do Wonders for Spark Stock
As Spark Therapeutics gets acquired, existing shareholders, and Roche investors, will need to eveluate the merits of the deal.
Is Tilray Stock a Must-Buy Following New Partnership?
Tilray stock is still very expensive, even after its partnership with Novartis' Sandoz. However, TLRY is in a very tradable range.
Novartis Layoffs 2018: NVS to Cut 2,000 + Jobs
Novartis (NVS) announced that it was laying off 2,000 workers in 2018 as part of a global restructuring, according to a Tuesday announcement.
Novartis Stock Pops on Alcon Spinoff News
Novartis (NVS) stock got a boost today after the company announced plans to spin off its Alcon business sometime next year.
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
Novartis AG (ADR) Stock Drops on Q1 Earnings Miss
Novartis (NVS) stock took a hit on Thursday following the release of its earnings report for the first quarter of the year.
A Big Bet on Gene Therapy Is Just What Novartis AG (ADR) Stock Needs
Novartis put its excess cash to good use by broadening its business into the gene therapy market. Competition could prove tough for NVS stock, but Novartis is ready for the challenge ahead.
AveXis Inc Stock Skyrockets on Novartis Deal
AveXis (AVXS) stock was flying high to day following news of am $8.7 billion deal that will have Novartis (NVS) acquiring it.
GlaxoSmithKline plc (ADR) Stock Jumps on $13 Billion Novartis Deal
GlaxoSmithKline (GSK) stock was up today on news of a $13 billion deal with Novartis (NVS) that it set to close in Summer 2018.
Novartis AG (NVS) a Buy on High-Level Quant Score
Novartis AG (NYSE:NVS) is a member of the 134 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS's market value is $200.3 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for NVS puts it 15 among the 134 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 109 among the 782 companies in the sector, and number 639 in the nearly 5,000 company Portfolio Grader universe.
Novartis AG (NVS) a Buy on Healthy Quant Score
The current recommendation of Buy for Novartis AG (NYSE:NVS) is derived using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. NVS has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.
3 Stocks to Watch on Friday: Novartis AG (ADR) (NVS), Nutanix Inc (NTNX) and Zumiez Inc. (ZUMZ)
Amazon (AMZN) explores online pharmaceuticals with Novartis AG (NVS), Nutanix (NTNX) and Zumiez (ZUMZ) report on their quarterly earnings.
Novartis AG (NVS) a Buy on Solid Earnings Visibility
Novartis AG (NYSE:NVS) is classified as a constituent of the 133 company Pharmaceuticals GICS industry group, which is a segment of the 781 company GICS Health Care sector. NVS has a market value of $195.5 billion which is in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 23 among the 133 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 166 among the 781 companies in the sector, and number 1,096 in the nearly 5,000 company Portfolio Grader universe.
Improving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy
The current recommendation of Buy for Novartis AG (NYSE:NVS) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The shares have been upgraded from a Hold to a Buy in the last week.
